TW reports grants from the Health Foundation supporting research framework for Business for Health (a community interest company or social venture) and for Open Life Data Framework; reports consulting fees from her work as CEO of Collider Health (projects listed on the website), including projects with National Innovation Centre for Ageing and (unpaid) secretariat services to All-Party Parliamentary Group for Longevity; sits on the British Standards Institute standards group for AI in health and care and Ada Lovelace Advisory Board on Health Inequalities; and is a trustee for the British Society for Research on Ageing. LC and NP report Internet of Caring Things, a 5-year programme jointly funded by North of Tyne Combined Authority and Newcastle University and led by the UK National Innovation Centre for Ageing. NB reports grants from the National Institutes of Health (P01AG021654), Nathan Shock Center of Excellence for the basic Biology of Aging (P30AG038072), and Einstein-Paul Glenn Foundation for Medical Research Center for the Biology of Human Aging; and executive roles with Longevity Biotech Association and Health Longevity Medical Society. JB reports that he is a member of the House of Lords. LSC reports funding from Biotechnology and Biological Sciences Research Council (BB/W01825X/1) and Medical Research Council; BIRAX and Diabetes UK; Public Health England (now UK Health Security Agency); Mellon Longevity Science Programme; UK SPINE (Research England), University of Oxford Medical Sciences Division and Wellcome Trust COVID Bridge Fund; John Fell Fund, University of Oxford; and Elysium Health. LSC also reports her role as co-director of UK Ageing networks and BLAST ageing network (UKRI funded) and voluntary roles with All Party Parliamentary Group for Longevity (UK); European Geriatric Medicine Society special interest group in Ageing Biology; Clinical and Translational Theme panel, Biochemical Society (UK); and Medical Research Council Ageing Research Steering Group. DF reports grants from the Global Center for Reproductive Longevity and Equality (NIH/NCI UG3CA268105-02, NIH/NIA P01AI153559-02, NIH/NIA P01AG066591-02, NIH/NIA U54AG075932-02, NIH/NIA R01 AG 082474-01, and NASA/UW Pro2379); Department for Defense on Strategies to Augment Ketosis for Enhanced Readiness and Disease Reversal; and consulting fees from Human Operations, Edifice Health, Cosmica, and Longevity Fund. HE reports consulting fees from Meadows Mental Health Policy Institute, The Baker Institute for Public Policy at Rice University, Kooth, The Guide App, and PRODEO; honoraria from Global Brain Health Institute (University of California San Francisco and Trinity College Dublin); and support to attend meetings from the Euro-Mediterranean Economists Association. AR is the CEO of Our Future Health that receives grants from Innovate UK and Alnylam, Amgen, AstraZeneca, Boehringer Ingelheim, Exact Sciences, GSK, Illumina, Janssen Research & Development, MSD, Novo Nordisk, Pfizer, Randox Laboratories, Regeneron Genetics Center, Roche, Thermo Fisher Scientific; is a non-executive board member of SNOMED; and is a shareholder in GSK. AS reports that he is co-organiser of The Longevity Forum and receives funding from the Economic and Social Research Council (grant T002204). RS reports consulting fees from Muhdo Health, Domo Health, and Charoen Pokphand Group. All other authors declare no competing interests. A list of references for further reading is available in the appendix.